Pipeline Reports

confidio, logo, maze

Medical and Pharmacy Benefit Drugs

This Pipeline Report is focused on potentially budget-busting medications. We bring you information on

  • What these drugs are used for;
  • How common those conditions are
  • Current treatments for those conditions;
  • How much the current treatments cost; and
  • What to expect when these drugs have been approved.

Most importantly, as a trusted advisor, Confidio recommends viable strategies for managing these expensive treatments.

There are three sections in this report:

  • Top Five: our pick of products recently approved or pending approval that we believe warrant the most attention
  • Recent FDA Approvals: detailed information on recently approved high-cost drugs under both the medical and pharmacy benefit
  • Anticipated Approvals: summary table for potentially high-cost products under development
Confidio, pipeline report, 2021, pharmacy, medication

Q4 2021

Confidio, Insights, Drug Report, FDA, Approval, Upcoming, Q3, 2021

Q3 2021

Confidio, Insights, Drug Report, FDA, Approval, Upcoming, Q2, 2021

Q2 2021

Confidio, Insights, Drug Report, FDA, Approval, Upcoming, Q1, 2021

Q1 2021

The Latest Biosimilar Pipeline Report

This Biosimilar Pipeline Report is focused on anticipating approvals, launches and impact of biosimilar products. We bring you information on

  • Reference products and what they’re used for
  • Upcoming and past biosimilar approval dates
  • Expected and past biosimilar launch dates
  • Annual cost of the biosimilars and their reference products

First Half 2021

Confidio, Insights, Drug Report, FDA, Approval, Upcoming, Biosimilar, 2020

Second Half 2020

Confidio, Insights, Drug Report, FDA, Approval, Upcoming, Biosimilar

First Half 2020